Effects of HMG-CoA reductase inhibitor on experimental autoimmune myocarditis

Cardiovascular Drugs and Therapy

Volumn 26, Issue 2, 2012, Pages 121-130

  Liu, Xiaoman ^a   Li, Bo ^a   Wang, Wenke ^a   Zhang, Cheng ^a   Zhang, Mingxiang ^a   Zhang, Yun ^a   Xia, Yanfei ^a   Dong, Zhe ^a   Guo, Yuan ^a   An, Fengshuang ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

InflammationApoptosis; Rosuvastatin. EAM

Indexed keywords

CASPASE 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYOSIN HEAVY CHAIN ALPHA; ROSUVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG MEGADOSE; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL AUTOIMMUNE MYOCARDITIS; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CELL; HEART OUTPUT; HEMODYNAMIC PARAMETERS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LEFT VENTRICULAR FRACTIONAL SHORTENING; LOW DRUG DOSE; MOUSE; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; APOPTOSIS; AUTOIMMUNE DISEASES; CASPASE 3; ECHOCARDIOGRAPHY; FEMALE; FLUOROBENZENES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERLEUKIN-6; LIPIDS; MICE; MICE, INBRED BALB C; MYOCARDITIS; MYOCYTES, CARDIAC; MYOSIN HEAVY CHAINS; PYRIMIDINES; SULFONAMIDES; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR MYOSINS;

EID: 84862752882     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-012-6372-6     Document Type: Article

References (36)

1. Kallwellis-Opara A, Dorner A, Poller WC, Noutsias M, Kuhl U, Schultheiss HP, et al. Autoimmunological features in inflammatory cardiomyopathy. Clin Res Cardiol. 2007;96:469-80. (Pubitemid 47012552)
2. Kuhl U, Pauschinger M, Bock T, Klingel K, Schwimmbeck CP, Seeberg B, et al. Parvovirus B19 infection mimicking acute myocardial infarction. Circulation. 2003;108:945-50. (Pubitemid 37048223)
3. Cai G, Zhang J, Liu L, Shen Q. Successful treatment of experimental autoimmune myocarditis by adenovirus-mediated gene transfer of antisense CIITA. J Mol Cell Cardiol. 2005;38:593-605. (Pubitemid 40461823)
4. Neu N, Beisel KW, Traystman MD, Rose NR, Craig SW. Autoantibodies specific for the cardiac myosin isoform are found in mice susceptible to Coxsackievirus B3-induced myocarditis. J Immunol. 1987;138:2488-92. (Pubitemid 17051821)
5. Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002;420:78-84. (Pubitemid 35291443)
6. Azuma RW, Suzuki J, Ogawa M, Futamatsu H, Koga N, Onai Y, et al. HMG-CoA reductase inhibitor attenuates experimental autoimmune myocarditis through inhibition of T cell activation. Cardiovasc Res. 2004;64:412-20. (Pubitemid 39505420)
7. Zhou Q, Liao JK. Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr Pharm Des. 2009;15:467-78.
8. Cruz-Adalia A, Jimenez-Borreguero LJ, Ramirez-Huesca M, Chico-Calero I, Barreiro O, Lopez-Conesa E, et al. CD69 limits the severity of cardiomyopathy after autoimmune myocarditis. Circulation. 2010;122:1396-404.
9. Whaley-Connell A, Habibi J, Nistala R, Cooper SA, Karuparthi PR, Hayden MR, et al. Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment. Hypertension. 2008;51:474-80. (Pubitemid 351156435)
10. Calkin AC, Giunti S, Sheehy KJ, Chew C, Boolell V, Rajaram YS, et al. The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation. Diabetologia. 2008;51:1731-40.
11. Pan HY, Yamada H, Chida J, Wang S, Yano M, Yao M, et al. Upregulation of ectopic trypsins in the myocardium by influenza A virus infection triggers acute myocarditis. Cardiovasc Res. 2011;89:595-603.
12. Goser S, Ottl R, Brodner A, Dengler TJ, Torzewski J, Egashira K, et al. Critical role for monocyte chemoattractant protein-1 and macrophage inflammatory protein-1alpha in induction of experimental autoimmune myocarditis and effective anti-monocyte chemoattractant protein-1 gene therapy. Circulation. 2005;112:3400-7. (Pubitemid 43739554)
13. Li WM, Liu W, Gao C, Zhou BG. Immunoregulatory effects of atorvastatin on experimental autoimmune myocarditis in Lewis rats. Immunol Cell Biol. 2006;84:274-80.
14. Yano M, Matsumura T, Senokuchi T, Ishii N, Murata Y, Taketa K, et al. Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. Circ Res. 2007;100:1442-51. (Pubitemid 46834756)
15. Cicha I, Schneiderhan-Marra N, Yilmaz A, Garlichs CD, Goppelt- Struebe M. Monitoring the cellular effects of HMG-CoA reductase inhibitors in vitro and ex vivo. Arterioscler Thromb Vasc Biol. 2004;24:2046-50. (Pubitemid 39482428)
16. Takemoto M, Sun J, Hiroki J, Shimokawa H, Liao JK. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation. 2002;106:57-62. (Pubitemid 34747442)
17. Ni W, Egashira K, Kataoka C, Kitamoto S, Koyanagi M, Inoue S, et al. Antiinflammatory and antiarteriosclerotic actions of HMGCoA reductase inhibitors in a rat model of chronic inhibition ofnitric oxide synthesis. Circ Res. 2001;89:415-21. (Pubitemid 34132657)
18. Li Y, Heuser JS, Kosanke SD, Hemric M, CunninghamMW. Cryptic epitope identified in rat and human cardiac myosin S2 region induces myocarditis in the Lewis rat. J Immunol. 2004;172:3225-34. (Pubitemid 38263714)
19. Salek-Ardakani S, Croft M. Tumor necrosis factor receptor/tumor necrosis factor family members in antiviral CD8 T-cell immunity. J Interferon Cytokine Res. 2010;30:205-18.
20. Tang Z, McGowan BS, Huber SA, McTiernan CF, Addya S, Surrey S, et al. Gene expression profiling during the transition to failure in TNF-alpha over-expressing mice demonstrates the development of autoimmune myocarditis. J Mol Cell Cardiol. 2004;36:515-30. (Pubitemid 38469942)
21. Sivasubramanian N, Coker M, Kurrelmeyer K, MacLellan W, DeMayo F, Spinale F, et al. Left ventricular remodeling in transgenic mice with cardiac restricted overex-pression of tumor necrosis factor. Circulation. 2001;104:826-31. (Pubitemid 32762683)
22. Hedayat M, Mahmoudi MJ, Rose NR, Rezaei N. Proinflammatory cytokines in heart failure: double-edged swords. Heart Fail Rev. 2010;15:543-62.
23. Wu JL, Matsui S, Zong ZP, Nishikawa K, Sun BG, Katsuda S, et al. Amelioration of myocarditis by statin through inhibiting cross-talk between antigen presenting cells and lymphocytes in rats. J Mol Cell Cardiol. 2008;44:1023-31.
24. Yamauchi-Takihara K, Kishimoto T. Cytokines and their receptors in cardiovascular diseases-role of gp130 signalling pathway in cardiac myocyte growth and maintenance. Int J Exp Pathol. 2000;81:1-16. (Pubitemid 30171497)
25. Yu X, Kennedy R, Liu S. JAK2/STAT3, not ERK1/2, mediates interleukin-6-induced activation of inducible nitricoxide synthase and decrease in contractility of adult ventricular myocytes. J Biol Chem. 2003;278:16304-9. (Pubitemid 36799756)
26. Siwik D, Chang D, Colucci W. Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res. 2000;86:1259-65. (Pubitemid 30436667)
27. Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med. 2000;6:583-8. (Pubitemid 30305911)
28. Eriksson U, Kurrer MO, Schmitz N, Marsch SC, Fontana A, Eugster HP, et al. Interleukin-6-deficient mice resist development of autoimmune myocarditis associated with impaired upregulation of complement C3. Circulation. 2003;107:320-5. (Pubitemid 36135231)
29. Node K, Fujita M, Kitakaze M, Hori M, Liao JK. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation. 2003;108:839-43. (Pubitemid 37022126)
30. Green D, Reed J. Mitochondria and apoptosis. Science. 1998;281:1309-12. (Pubitemid 28406816)
31. Haudek S, Taffet G, Schneider M, Mann D. TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathways. J Clin Invest. 2007;117:2692-791.
32. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature. 1998;391:43-50. (Pubitemid 28079208)
33. Ito M, Adachi T, Pimentel DR, Ido Y, Colucci WS. Statins inhibit beta-adrenergic receptor-stimulated apoptosis in adult rat ventricular myocytes via a Rac1-dependent mechanism. Circulation.2004;110:412-8. (Pubitemid 38993850)
34. Abraham SS, Osorio JC, Homma S, Wang J, Thaker HM, Liao JK, et al. Simvastatin preserves cardiac function in genetically determined cardiomyopathy. J Cardiovasc Pharmacol. 2004;43:454-61. (Pubitemid 38270614)
35. Bergmann MW, Rechner C, Freund C, Baurand A, El Jamali A, Dietz R. Statins inhibit reoxygenation-induced cardiomyocyte apoptosis: role for glycogen synthase kinase 3beta and transcription factor beta-catenin. J Mol Cell Cardiol. 2004;37:681-90. (Pubitemid 39194560)
36. Sharma H, Pathan RA, Kumar V, Javed S, Bhandari U. Antiapoptotic potential of rosuvastatin pretreatment in murine model of cardiomyopathy. Int J Cardiol. 2011;150:193-200.